Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Additive Effect of Dorzolamide/Timolol on Latanoprost in Glaucoma
NCT00906594Phase 4
Key facts
- Status
- Completed
- Start
- Sep 2007
- Primary completion
- Jan 2008
- Countries
- 1
- Sponsor
- Universidade de São Paulo
- Modality
- Small Molecules
- Drugs
- dorzolamide
- Conditions
- Glaucomaocular hypertension
01
Overview
Phase 4, randomised, open-label trial of dorzolamide in Glaucoma and ocular hypertension (2 arms), sponsored by Universidade de São Paulo. Primary endpoint: Additional Intra-ocular Pressure Reduction at 4 weeks. Started Sep 2007; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Latanoprost Monotherapy
Continued Latanoprost monotherapy
Latanoprost + Cosopt
Latanoprost plus Dorzolamide/Timolol fixed combination
03
Who it enrols
Adult patients with open-angle glaucoma or ocular hypertension with elevated IOP despite latanoprost monotherapy. Excludes patients with recent ocular surgery or contraindications to beta-blockers.
04
Endpoints
Primary
Additional Intra-ocular Pressure Reduction
Beyond the preview
Go deeper on NCT00906594.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00906594.